Heron Therapeutics (NASDAQ:HRTX – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Heron Therapeutics to related companies based on the strength of its analyst recommendations, risk, earnings, valuation, profitability, institutional ownership and dividends.
Valuation and Earnings
This table compares Heron Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Heron Therapeutics | $148.22 million | -$20.19 million | -2.67 |
| Heron Therapeutics Competitors | $18.55 billion | $3.23 billion | 561.62 |
Heron Therapeutics’ rivals have higher revenue and earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Profitability
This table compares Heron Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heron Therapeutics | -14.55% | -277.36% | -8.76% |
| Heron Therapeutics Competitors | -2,398.26% | -203.62% | -15.08% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Heron Therapeutics and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heron Therapeutics | 1 | 3 | 0 | 0 | 1.75 |
| Heron Therapeutics Competitors | 7845 | 13797 | 25812 | 1039 | 2.41 |
Heron Therapeutics presently has a consensus price target of $2.00, suggesting a potential upside of 525.00%. As a group, “Pharmaceuticals” companies have a potential upside of 23.66%. Given Heron Therapeutics’ higher possible upside, equities research analysts plainly believe Heron Therapeutics is more favorable than its rivals.
Institutional and Insider Ownership
80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Heron Therapeutics rivals beat Heron Therapeutics on 8 of the 13 factors compared.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for patients in acute care settings, including cancer treatment and surgery. Its work includes medicines intended to prevent nausea and vomiting associated with chemotherapy and surgery, as well as treatments for postsurgical pain. Heron’s products include CINVANTI and APONVIE, injectable formulations of aprepitant used to help prevent nausea and vomiting in specified clinical settings. The company also developed ZYNRELEF, a combination of bupivacaine and meloxicam for postsurgical pain, and SUSTOL, an extended-release formulation of granisetron for chemotherapy-related nausea and vomiting.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
